The Centers for Medicare & Medicaid Services yesterday approved Louisiana’s Medicaid plan amendment allowing supplemental rebate agreement negotiations with prescription drug makers for Hepatitis C therapies. The new “modified subscription” model allows the state to cap gross expenditures for the Hepatitis C prescriptions for Medicaid and requires manufacturers to provide the drug’s lowest price negotiated in all states in the Medicaid program. “The high cost of prescription drugs is one of the greatest challenges in our health care system,” said CMS Administrator Seema Verma, “and Louisiana’s innovative approach to leveraging a subscription model to promote access to hepatitis C therapy is a great example of how states can lead in designing solutions.” The amendment goes into effect July 1. CMS has approved similar state plan amendments for Washington, Oklahoma, Michigan and Colorado. This is the second one to focus on Hepatitis C.

Related News Articles

Headline
The Senate Finance Committee June 16 released its draft legislative text as part of the Senate’s version of the budget reconciliation bill. The committee,…
Headline
The Centers for Medicare & Medicaid Services June 13 announced it approved state plan amendments to expand Medicaid access to care for tribal communities…
Headline
The AHA June 16 released a fact sheet with analysis on the impact to rural patients and hospitals from proposed Medicaid cuts by Congress. The analysis found…
Headline
The latest video in the AHA’s series “Medicaid: Real Lives, Real Care” features Jennifer Clowers, regional chief financial officer of Our Lady of the Lake…
Headline
The AHA June 10 released a new video in its series, “Medicaid: Real Lives, Real Care,” that features Missouri Hospital Association President and CEO Jon…
Headline
The White House June 6 issued a memorandum directing the Secretary of the Department of Health and Human Services “to take appropriate action to eliminate…